CeleCor Therapeutics

CeleCor Therapeutics, Inc. is a biotechnology company focused on developing first-point-of-contact therapies to improve the treatment of severe heart attacks, particularly ST-segment elevation myocardial infarction (STEMI). The company's lead clinical-stage candidate drug is zalunfiban, a novel small-molecule inhibitor of the platelet GPIIb/IIIa (αIIbβ3) receptor, designed for easy subcutaneous administration.